Literature DB >> 6886028

Radioreceptor and high-performance liquid chromatographic assays for the calcium channel antagonist nitrendipine in serum.

R A Janis, G J Krol, A J Noe, M Pan.   

Abstract

Radioreceptor and high-performance liquid chromatographic (HPLC) assays for nitrendipine were developed and applied to the analysis of serum samples. The HPLC assay required both extraction and concentration of the serum samples, whereas the radioreceptor assay involved only direct dilution of the serum. The HPLC assay, in contrast to the radioreceptor assay, can be used for detection and quantitative analysis of biologically inactive metabolites. The radioreceptor assay is based on the competition between nitrendipine in serum and [3H]nitrendipine for high-affinity binding sites on cardiac membranes. Forty-two serum samples were obtained from five volunteers, and the HPLC and radioreceptor assay results were compared. A correlation coefficient of 0.98 was found between the results of the two assays within the nitrendipine serum concentration range of 1 to 20 ng/ml. No significant levels of active metabolites or any other interferences were found. The radioreceptor assay provides a specific and sensitive alternative to HPLC; it is rapid and inexpensive and with minor modifications may be applicable to most presently available Ca2+ channel antagonists.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6886028     DOI: 10.1002/j.1552-4604.1983.tb02734.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  3 in total

1.  Simple and reliable radioreceptor assay for beta-adrenoceptor antagonists and active metabolites in native human plasma.

Authors:  A Wellstein; D Palm; G Wiemer; M Schäfer-Korting; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

2.  High-affinity antibodies to the 1,4-dihydropyridine Ca2+-channel blockers.

Authors:  K P Campbell; A Sharp; M Strom; S D Kahl
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

Review 3.  Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease.

Authors:  M S Langley; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.